DU
IOVA icon

Delphia (USA)’s Iovance Biotherapeutics IOVA Stock Holding History

Delphia (USA)’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,587
Closed -$67.7K – 297
2022
Q4 		$67.7K Sell
10,587
-6,204
-37% -$48.4K 0.08% 262
2022
Q3 		$161K Sell
16,791
-8,269
-33% -$95.4K 0.18% 211
2022
Q2 		$277K Buy
25,060
+8,000
+47% +$105K 0.19% 193
2022
Q1 		$284K Buy
+17,060
New +$264K 0.21% 180

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Delphia (USA)'s IOVA Position: Q1 2023 in Review

Delphia (USA) sold out of Iovance Biotherapeutics (IOVA) in Q1 2023, closing a stake of 10,587 shares — an estimated $67.7K sold.

Delphia (USA) first reported a position in IOVA in Q1 2022 and held it in 4 quarters. The position peaked at $284K in Q1 2022. 228 funds tracked by Wall St. Rank hold IOVA as of Q1 2023.

  • Delphia (USA) reported no remaining Iovance Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Delphia (USA) sold 10,587 Iovance Biotherapeutics shares in Q1 2023, an estimated $67.7K.
  • Delphia (USA) first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 4 quarters.
  • Delphia (USA)'s Iovance Biotherapeutics position peaked at $284K in Q1 2022.
  • 228 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2023.

Based on Delphia (USA)'s 13F filing for Q1 2023, filed 15 May 2023.